{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:11:48Z","timestamp":1718763108818},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00228-016-2119-9","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T10:36:09Z","timestamp":1472121369000},"page":"1373-1379","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia"],"prefix":"10.1007","volume":"72","author":[{"given":"Na\u00efm","family":"Bouazza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Gozalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanetee","family":"Busiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Berdugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saik","family":"Urien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"key":"2119_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-8587(13)70059-7","volume":"1","author":"K Busiah","year":"2013","unstructured":"Busiah K, Drunat S, Vaivre-Douret L, Bonnefond A, Simon A, Flechtner I, G\u00e9rard B, Pouvreau N, Elie C, Nimri R, De Vries L, Tubiana-Rufi N, Metz C, Bertrand AM, Nivot-Adamiak S, de Kerdanet M, Stuckens C, Jennane F, Souchon PF, Le Tallec C, D\u00e9sir\u00e9e C, Pereira S, Dechaume A, Robert JJ, Phillip M, Scharfmann R, Czernichow P, Froguel P, Vaxillaire M, Polak M, Cav\u00e9 H, French NDM study group (2013) Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected]. Lancet Diabetes Endocrinol 1:199\u2013207","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2119_CR2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMoa055068","volume":"355","author":"AP* Babenko","year":"2006","unstructured":"Babenko AP*, Polak M*, Cav\u00e9 H, Busiah K, Czernichow P, Scharfmann R, et al. (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456\u2013466","journal-title":"N Engl J Med"},{"key":"2119_CR3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2337\/diacare.28.3.758","volume":"28","author":"E Codner","year":"2005","unstructured":"Codner E, Flanagan S, Ellard S, Garc\u00eda H, Hattersley AT (2005) High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 28:758\u2013759","journal-title":"Diabetes Care"},{"key":"2119_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJMoa061759","volume":"355","author":"ER* Pearson","year":"2006","unstructured":"Pearson ER*, Flechtner I*, Nj\u00f8lstad PR*, Malecki MT, Flanagan SE, Larkin B, et al. (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467\u2013477","journal-title":"N Engl J Med"},{"key":"2119_CR5","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diabetes.53.10.2713","volume":"53","author":"JV Sagen","year":"2004","unstructured":"Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. (2004) Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713\u20132718","journal-title":"Diabetes"},{"key":"2119_CR6","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1210\/jc.2004-1241","volume":"89","author":"A Zung","year":"2004","unstructured":"Zung A, Glaser B, Nimri R, Zadik Z (2004) Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 89:5504\u20135507","journal-title":"J Clin Endocrinol Metab"},{"key":"2119_CR7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diacare.17.9.1026","volume":"17","author":"T Rydberg","year":"1994","unstructured":"Rydberg T, J\u00f6nsson A, R\u00f8der M, Melander A (1994) Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17:1026\u20131030","journal-title":"Diabetes Care"},{"key":"2119_CR8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bcp.2009.08.003","volume":"78","author":"OL Zharikova","year":"2009","unstructured":"Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GDV, et al. (2009) Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol 78:1483\u20131490","journal-title":"Biochem Pharmacol"},{"key":"2119_CR9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/bdd.706","volume":"31","author":"L Zhou","year":"2010","unstructured":"Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, et al. (2010) Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 31:228\u2013242","journal-title":"Biopharm Drug Dispos"},{"key":"2119_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2796.2010.02257.x","volume":"268","author":"T Tirkkonen","year":"2010","unstructured":"Tirkkonen T, Heikkil\u00e4 P, Huupponen R, Laine K (2010) Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med 268:359\u2013366","journal-title":"J Intern Med"},{"key":"2119_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","volume":"77","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Brockm\u00f6ller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1\u201316","journal-title":"Clin Pharmacol Ther"},{"key":"2119_CR12","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.2337\/dc14-3056","volume":"38","author":"D Carmody","year":"2015","unstructured":"Carmody D, Beca FA, Bell CD, Hwang JL, Dickens JT, Devine NA, Mackay DJ, Temple IK, Hays LR, Naylor RN, Philipson LH, Greeley SA (2015) Role of noninsulin therapies alone or in combination in chromosome 6q24-related transient neonatal diabetes: sulfonylurea improves but does not always normalize insulin secretion. Diabetes Care 38:e86\u2013e87","journal-title":"Diabetes Care"},{"key":"2119_CR13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s00125-015-3593-9","volume":"58","author":"BW Thurber","year":"2015","unstructured":"Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, SA G, United States Neonatal Diabetes Working Group (2015) Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia 58:1430\u20131435","journal-title":"Diabetologia"},{"issue":"12","key":"2119_CR14","doi-asserted-by":"crossref","first-page":"E2709","DOI":"10.1210\/jc.2014-2494","volume":"99","author":"D Carmody","year":"2014","unstructured":"Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA (2014) Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab 99(12):E2709\u2013E2714","journal-title":"J Clin Endocrinol Metab"},{"key":"2119_CR15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2125.2006.02836.x","volume":"63","author":"JJ Lilja","year":"2007","unstructured":"Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ (2007) Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 63:732\u2013740","journal-title":"Br J Clin Pharmacol"},{"key":"2119_CR16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1997.00571.x","volume":"43","author":"T Rydberg","year":"1997","unstructured":"Rydberg T, J\u00f6nsson A, Karlsson MO, Melander A (1997) Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 43:373\u2013381","journal-title":"Br J Clin Pharmacol"},{"key":"2119_CR17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1067\/mcp.2002.127495","volume":"72","author":"M Niemi","year":"2002","unstructured":"Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivist\u00f6 KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72:326\u2013332","journal-title":"Clin Pharmacol Ther"},{"key":"2119_CR18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1373\/clinchem.2005.050864","volume":"51","author":"G Hoizey","year":"2005","unstructured":"Hoizey G, Lamiable D, Trenque T, Robinet A, Binet L, Kaltenbach ML, et al. (2005) Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem 51:1666\u20131672","journal-title":"Clin Chem"},{"key":"2119_CR19","unstructured":"Beal SL, Sheiner LB (1998) NONMEM user guides (I\u2013VIII). Univ. Calif. San Franc. San Franc. CA"},{"key":"2119_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","author":"R Ihaka","year":"1996","unstructured":"Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299\u2013314","journal-title":"J Comput Graph Stat"},{"key":"2119_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","volume":"59","author":"J Parke","year":"1999","unstructured":"Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Prog Biomed 59:19\u201329","journal-title":"Comput Methods Prog Biomed"},{"key":"2119_CR22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11:558\u2013569","journal-title":"AAPS J"},{"key":"2119_CR23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90:154\u2013166","journal-title":"Comput Methods Prog Biomed"},{"key":"2119_CR24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clpt.2005.06.006","volume":"78","author":"OQP Yin","year":"2005","unstructured":"Yin OQP, Tomlinson B, Chow MSS (2005) CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 78:370\u2013377","journal-title":"Clin Pharmacol Ther"},{"key":"2119_CR25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1067\/mcp.2002.122476","volume":"71","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Brockm\u00f6ller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286\u2013296","journal-title":"Clin Pharmacol Ther"},{"key":"2119_CR26","doi-asserted-by":"crossref","unstructured":"Beltrand J, Elie C, Busiah K, Fournier E, Boddaert N, Bahi-Buisson N, Vera M, Bui Quoc E, Ingster Moati I, Berdugo M, Simon A, Gozalo C, Djerada Z, Flechtner I, Treluyer JM, Scharfmann R, Cav\u00e9 H, Vaivre-Douret L, Polak M, on behalf of de GlidKir study group (2015) Sulfonylurea benefits neurological and psychomotor functions in patients with neonatal diabetes due to potassium channel mutations. Diabetes Care","DOI":"10.2337\/dc15-0837"},{"key":"2119_CR27","unstructured":"Beltrand J, Busiah K, Berdugo M, Scharfmann R, Tr\u00e9luyer JM, Elie C, Polak M (2015) Pharmacokinetics (PK) of a new suspension of glibenclamide for use in young patients and infants with neonatal diabetes. Oral presentations. European Society for Pediatric Endocrinology (ESPE), Barcelona, and International Society for Paediatric Diabetes (ISPAD)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2119-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:52:53Z","timestamp":1718761973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2119"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2119-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}